BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37256526)

  • 1. Re-irradiation for recurrent high-grade glioma: an analysis of prognostic factors for survival and predictors of radiation necrosis.
    Moore-Palhares D; Chen H; Keith J; Wang M; Myrehaug S; Tseng CL; Detsky J; Perry J; Lim-Fat MJ; Heyn C; Maralani P; Lipsman N; Das S; Sahgal A; Soliman H
    J Neurooncol; 2023 Jul; 163(3):541-551. PubMed ID: 37256526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose salvage re-irradiation for recurrent/progressive adult diffuse glioma: healing or hurting?
    Gupta T; Maitre M; Maitre P; Goda JS; Krishnatry R; Chatterjee A; Moiyadi A; Shetty P; Epari S; Sahay A; Patil V; Jalali R
    Clin Transl Oncol; 2021 Jul; 23(7):1358-1367. PubMed ID: 33528810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reirradiation with concurrent bevacizumab for recurrent high-grade gliomas in adult patients.
    Schernberg A; Dhermain F; Ammari S; Dumont SN; Domont J; Patrikidou A; Pallud J; Dezamis É; Deutsch É; Louvel G
    Cancer Radiother; 2018 Feb; 22(1):9-16. PubMed ID: 29217134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypofractionated re-irradiation with bevacizumab for relapsed chemorefractory glioblastoma after prior high dose radiotherapy: a feasible option for patients with large-volume relapse.
    Tong E; Horsley P; Wheeler H; Wong M; Venkatesha V; Chan J; Kastelan M; Back M
    J Neurooncol; 2024 May; 168(1):69-76. PubMed ID: 38551747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone.
    Arvold ND; Shi DD; Aizer AA; Norden AD; Reardon DA; Lee EQ; Nayak L; Dunn IF; Golby AJ; Johnson MD; Claus EB; Chiocca EA; Ligon KL; Wen PY; Alexander BM
    J Neurooncol; 2017 Dec; 135(3):581-591. PubMed ID: 28975467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extent of re-excision, sequence/timing of salvage re-irradiation, and disease-free interval impact upon clinical outcomes in recurrent/progressive ependymoma.
    Gupta T; Maitre M; Gupta P; Krishnatry R; Chatterjee A; Moiyadi A; Shetty P; Singh V; Chinnaswamy G; Epari S; Sahay A; Patil V; GodaSastri J
    J Neurooncol; 2020 Apr; 147(2):405-415. PubMed ID: 32072441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival gain with re-Op/RT for recurred high-grade gliomas depends upon risk groups.
    Chun SJ; Park SH; Park CK; Kim JW; Kim TM; Choi SH; Lee ST; Kim IH
    Radiother Oncol; 2018 Aug; 128(2):254-259. PubMed ID: 29937212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cs-131 brachytherapy for patients with recurrent glioblastoma combined with bevacizumab avoids radiation necrosis while maintaining local control.
    Wernicke AG; Taube S; Smith AW; Herskovic A; Parashar B; Schwartz TH
    Brachytherapy; 2020; 19(5):705-712. PubMed ID: 32928486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO).
    Navarria P; Minniti G; Clerici E; Tomatis S; Pinzi V; Ciammella P; Galaverni M; Amelio D; Scartoni D; Scoccianti S; Krengli M; Masini L; Draghini L; Maranzano E; Borzillo V; Muto P; Ferrarese F; Fariselli L; Livi L; Pasqualetti F; Fiorentino A; Alongi F; di Monale MB; Magrini S; Scorsetti M
    J Neurooncol; 2019 Mar; 142(1):59-67. PubMed ID: 30515706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of Second Line Treatment of Recurrent High- Grade Glioma by re-Irradiation or Bevacizumab-based Chemotherapy: A Cross Sectional Study.
    Anvari K; Shahabadi M; Welsh JS; Javadinia SA; Zarei E
    Asian Pac J Cancer Prev; 2023 May; 24(5):1507-1511. PubMed ID: 37247269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re-Irradiation for Recurrent Gliomas: Treatment Outcomes and Prognostic Factors.
    Lee J; Cho J; Chang JH; Suh CO
    Yonsei Med J; 2016 Jul; 57(4):824-30. PubMed ID: 27189273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas.
    Dixit KS; Sachdev S; Amidei C; Kumthekar P; Kruser TJ; Gondi V; Grimm S; Lukas RV; Nicholas MK; Chmura SJ; Fought AJ; Mehta M; Raizer JJ
    J Neurooncol; 2021 Dec; 155(3):297-306. PubMed ID: 34689306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re-irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic score-report of the Radiation Oncology Group (ROG) of the German Cancer Consortium (DKTK).
    Combs SE; Niyazi M; Adeberg S; Bougatf N; Kaul D; Fleischmann DF; Gruen A; Fokas E; Rödel CM; Eckert F; Paulsen F; Oehlke O; Grosu AL; Seidlitz A; Lattermann A; Krause M; Baumann M; Guberina M; Stuschke M; Budach V; Belka C; Debus J; Kessel KA
    Cancer Med; 2018 May; 7(5):1742-1749. PubMed ID: 29573214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re-irradiation for recurrent glioma- the NCI experience in tumor control, OAR toxicity and proposal of a novel prognostic scoring system.
    Krauze AV; Peters C; Cheng J; Ning H; Mackey M; Rowe L; Cooley-Zgela T; Smart DD; Camphausen K
    Radiat Oncol; 2017 Nov; 12(1):191. PubMed ID: 29187219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients.
    Niyazi M; Jansen NL; Rottler M; Ganswindt U; Belka C
    Radiat Oncol; 2014 Dec; 9():299. PubMed ID: 25529015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing of re-irradiation in recurrent high-grade gliomas: a single institution study.
    Zemlin A; Märtens B; Wiese B; Merten R; Steinmann D
    J Neurooncol; 2018 Jul; 138(3):571-579. PubMed ID: 29520609
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Fleischmann DF; Unterrainer M; Bartenstein P; Belka C; Albert NL; Niyazi M
    J Neurooncol; 2017 Apr; 132(2):277-286. PubMed ID: 28102485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of an established prognostic score after re-irradiation of recurrent glioma.
    Kessel KA; Hesse J; Straube C; Zimmer C; Schmidt-Graf F; Schlegel J; Meyer B; Combs SE
    Acta Oncol; 2017 Mar; 56(3):422-426. PubMed ID: 28075197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial results of a phase II trial of
    Breen WG; Youland RS; Giri S; Jacobson SB; Pafundi DH; Brown PD; Hunt CH; Mahajan A; Ruff MW; Kizilbash SH; Uhm JH; Routman DM; Jones JE; Brinkmann DH; Laack NN
    J Neurooncol; 2022 Jul; 158(3):323-330. PubMed ID: 35583721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation.
    Fleischmann DF; Unterrainer M; Corradini S; Rottler M; Förster S; la Fougère C; Siepmann T; Schwaiger M; Bartenstein P; Belka C; Albert NL; Niyazi M
    PLoS One; 2019; 14(7):e0216111. PubMed ID: 31339892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.